APO E GENOTYPE AND CYP2C19 GENOTYPE

This home genetic test profiles APOE (E2/E3/E4) and CYP2C19 variants from a simple buccal swab to provide genetic insight into lipid handling and drug metabolism. APOE genotype helps refine cardiovascular risk assessment and inform lipid‑management strategies, while CYP2C19 status predicts response to clopidogrel and other CYP2C19‑metabolized medications so clinicians in Dubai and across the UAE can better tailor antiplatelet therapy. Samples are collected at home and processed in an accredited laboratory via Touch Connect, and results should be reviewed with your cardiologist or treating physician to guide treatment choices and monitoring.

• APOE genotype — alleles: ε2, ε3, ε4
• APOE-based cardiovascular risk assessment
• CYP2C19 genotype — alleles: *1, *2, *3, *17
• CYP2C19 predicted metabolizer status (Poor / Intermediate / Normal / Rapid / Ultra‑rapid) and clopidogrel response guidance

• Home saliva/buccal swab collection kit with courier pickup for APOE and CYP2C19 testing
• APOE genotype (ε2/ε3/ε4) report to inform lipid-related cardiovascular risk stratification
• CYP2C19 metabolizer status to guide antiplatelet and other cardiovascular drug selection (e.g., clopidogrel)
• Actionable, clinician-friendly report with personalized recommendations for UAE/Dubai healthcare providers
• Secure, UAE-compliant data handling and electronic delivery of results for physician review

• Home-collected cheek swab kit with secure pickup and processing available across Dubai and the UAE
• APOE genotype (ε2/ε3/ε4) report to clarify lipid metabolism profiles and refine cardiovascular risk assessment
• CYP2C19 metabolizer status to inform likely response to clopidogrel and guide antiplatelet therapy decisions
• Laboratory-validated, clinician-ready results with clear interpretation for cardiologists and primary care teams in the UAE
• Secure online delivery of results with optional teleconsultation to discuss actionable next steps within Dubai healthcare pathways

• Home buccal swab collection with Dubai-wide pickup for APOE and CYP2C19 genotyping
• APOE allele report to refine lipid-related cardiovascular risk profiling and prevention planning
• CYP2C19 metabolizer status to inform antiplatelet therapy choices (e.g., clopidogrel responsiveness) for safer prescribing
• Clinically validated results delivered securely as an electronic report, compatible with UAE healthcare providers and follow-up consultations